SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that Stelo, the first over-the-counter ...
Dexcom on Tuesday announced its first generative AI feature for its Stelo biosensor that gives users a personalized weekly report about their glucose. The company has been building a generative AI ...
In March, the FDA approved DexCom Inc‘s (NASDAQ:DXCM) Stelo Glucose Biosensor System as the first over-the-counter (OTC) continuous glucose monitor (CGM). The Dexcom Stelo Glucose Biosensor System is ...
Stelo will be the first glucose biosensor in the US cleared for use without a prescription Indicated for use for people 18 years and older who are not using insulin therapy A small, wearable sensor ...
San Diego’s Dexcom began sales this week of Stelo, the industry’s first FDA-approved continuous glucose monitor that doesn’t require a prescription. With a two-pack of the biosensor costing just under ...
Dexcom on Tuesday announced an artificial intelligence feature for its Stelo continuous glucose monitor that gives users a personalized look into how meals, sleep and activity impact their glucose ...
Stelo is a small biosensor worn on the back of the upper arm that leverages Dexcom’s most accurate glucose sensing technology. 5 It is specifically designed to provide the 125 million Americans 6 with ...
Stream NBC 5 for free, 24/7, wherever you are. Stelo is an over-the-counter CGM that pokes through the skin to measure real-time blood sugar levels. The sensor launched in August and can be used by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback